Immunitybio Inc (IBRX) Stock Price, Quote & News

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 696 5235

Website: immunitybio.com

Address:

3530 John Hopkins Court, San Diego, United States

Stayinvest Oct. 4 at 10:40 PM

$IBRX interesting interview

0 · Reply

Stayinvest Oct. 4 at 10:39 PM

$IBRX https://youtu.be/OtbRBfnkxRU?si=bfum8wQvrq13iwfS

0 · Reply

Turnpiker Oct. 4 at 10:29 PM

$IBRX https://www.brookings.edu/articles/fdas-new-commissioners-national-priority-voucher-has-lofty-goals-can-it-deliver/

0 · Reply

rubraquercus Oct. 4 at 9:26 PM

$IBRX just a matter of time...ImmunityBio (IBRX) reported a 60% quarter-over-quarter revenue growth in the second quarter of 2025, reaching $26.4 million, driven by strong sales of its bladder cancer drug ANKTIVA. This growth represents an increase from the first quarter's revenue of $16.5 million and reflects the drug's growing commercial adoption and expanded market reach.

1 · Reply

Stocktud Oct. 4 at 8:46 PM

$IBRX https://www.aljazeera.com/amp/news/2025/9/30/saudi-fund-kushners-firm-to-buy-games-maker-electronic-arts-in-55bn-deal

0 · Reply

IBRXrallypossum002100 Oct. 4 at 7:35 PM

$IBRX This might have been written by AI. There are multiple mistakes...some pretty big ones. Anyway...for what it's worth: https://seekingalpha.com/article/4827740-immunitybio-small-bet-warranted

1 · Reply

Judykay Oct. 4 at 7:03 PM

$IBRX Will he come back or is he here still?

1 · Reply

CagedMoney Oct. 4 at 6:51 PM

$IBRX

1 · Reply

PoorOffTrading Oct. 4 at 6:48 PM

$IBRX The quarterly super dip before the earnings is coming, the stock typically drop to near $2.10s. That’s where I’ll be and ride it to the quarterly $3. Then let it go before it goes back to $2.70s.

1 · Reply

Intime32 Oct. 4 at 2:05 PM

$IBRX Still here been away from board, scrolling back don't see much from Dr. PSS anymore posted, no more Tuesday Evening Podcasts, X Postings, nothing on ME verbal agreements, has BP Drained the ImmunityBio Tank Dry, with help from Hot Air Makary & BP Rep. Power Tripper BIGOT: Vinay Prasad (CIBER), ImmunityBio getting anything through Prasad will be a Battle he hates Dr. PSS's accomplishment's more a jealousy issue, plus Dr PSS stood up to Prasad back in 2017, Bigots can not handle being put in there place, they are very Vindictive for ever!

0 · Reply

ImmunityBio: A Small Bet Is Warranted

Sep 11, 2025, 12:26 PM EDT - 23 days ago

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

Sep 8, 2025, 8:30 AM EDT - 26 days ago

ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

Aug 26, 2025, 8:30 AM EDT - 5 weeks ago

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

Aug 19, 2025, 8:30 AM EDT - 6 weeks ago

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Aug 13, 2025, 8:30 AM EDT - 7 weeks ago

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

Aug 11, 2025, 8:30 AM EDT - 7 weeks ago

ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Aug 5, 2025, 7:00 AM EDT - 2 months ago

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Jul 25, 2025, 6:03 AM EDT - 2 months ago

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

Jul 25, 2025, 6:00 AM EDT - 2 months ago

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

Jul 21, 2025, 10:45 AM EDT - 2 months ago

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval

Jul 7, 2025, 9:43 PM EDT - 3 months ago

UK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jun 12, 2025, 9:09 AM EDT - 4 months ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 3, 2025, 8:45 AM EDT - 4 months ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 2, 2025, 9:00 AM EDT - 4 months ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

May 27, 2025, 8:00 AM EDT - 4 months ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 12, 2025, 6:30 AM EDT - 5 months ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 5, 2025, 5:05 PM EDT - 5 months ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 9:21 AM EDT - 5 months ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 6:30 AM EDT - 5 months ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

Apr 29, 2025, 12:50 PM EDT - 5 months ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 28, 2025, 8:30 AM EDT - 5 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 21, 2025, 4:21 PM EDT - 5 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 15, 2025, 8:00 AM EDT - 6 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 8, 2025, 7:30 AM EDT - 6 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 7, 2025, 5:00 AM EDT - 6 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 3, 2025, 5:54 PM EDT - 6 months ago

ImmunityBio: Taking Care Of Business

Mar 26, 2025, 6:00 AM EDT - 6 months ago

ImmunityBio to Host Investor Day

Mar 13, 2025, 9:00 AM EDT - 7 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 7, 2025, 1:47 AM EST - 7 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 3, 2025, 7:30 AM EST - 7 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Feb 27, 2025, 7:10 PM EST - 7 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 19, 2025, 9:00 AM EST - 8 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 13, 2025, 3:05 PM EST - 8 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 29, 2025, 8:30 AM EST - 8 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 27, 2025, 9:00 AM EST - 8 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 17, 2025, 2:05 PM EST - 9 months ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 16, 2025, 2:25 PM EST - 9 months ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 15, 2025, 5:20 PM EST - 9 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 9 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 6, 2025, 9:00 AM EST - 9 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Dec 16, 2024, 12:24 AM EST - 10 months ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 13, 2024, 2:40 PM EST - 10 months ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 12, 2024, 8:00 AM EST - 10 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 11, 2024, 7:30 AM EST - 10 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 10 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Nov 21, 2024, 10:00 AM EST - 11 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

Nov 19, 2024, 9:00 AM EST - 11 months ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Nov 19, 2024, 8:00 AM EST - 11 months ago

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Stayinvest Oct. 4 at 10:40 PM

$IBRX interesting interview

0 · Reply

Stayinvest Oct. 4 at 10:39 PM

$IBRX https://youtu.be/OtbRBfnkxRU?si=bfum8wQvrq13iwfS

0 · Reply

Turnpiker Oct. 4 at 10:29 PM

$IBRX https://www.brookings.edu/articles/fdas-new-commissioners-national-priority-voucher-has-lofty-goals-can-it-deliver/

0 · Reply

rubraquercus Oct. 4 at 9:26 PM

1 · Reply

Stocktud Oct. 4 at 8:46 PM

$IBRX https://www.aljazeera.com/amp/news/2025/9/30/saudi-fund-kushners-firm-to-buy-games-maker-electronic-arts-in-55bn-deal

0 · Reply

IBRXrallypossum002100 Oct. 4 at 7:35 PM

$IBRX This might have been written by AI. There are multiple mistakes...some pretty big ones. Anyway...for what it's worth: https://seekingalpha.com/article/4827740-immunitybio-small-bet-warranted

1 · Reply

Judykay Oct. 4 at 7:03 PM

$IBRX Will he come back or is he here still?

1 · Reply

CagedMoney Oct. 4 at 6:51 PM

$IBRX

1 · Reply

PoorOffTrading Oct. 4 at 6:48 PM

1 · Reply

Intime32 Oct. 4 at 2:05 PM

0 · Reply

RoyalFlushIBRX Oct. 4 at 1:22 PM

$IBRX

1 · Reply

mainesouth36 Oct. 4 at 1:15 PM

$IBRX I do not see the 500 mill news from the company to confirm. I did read the Bixby article.

1 · Reply

Judykay Oct. 4 at 12:38 PM

$IBRX Ethos come back, I wasn't finished.

1 · Reply

CaptObvious3 Oct. 4 at 8:48 AM

$IBRX Dear Heavenly Father, deliver us!!!!

2 · Reply

svertical1 Oct. 4 at 6:25 AM

$IBRX One of the biggest of the biggest! Sorry, no longer a subscriber, but headline looks on target. https://www.zerohedge.com/markets/goldman-biggest-short-squeeze-meme-stock-massacre Sent from my iPhone

2 · Reply

MrsStocka Oct. 4 at 3:43 AM

$IBRX

0 · Reply

Judykay Oct. 4 at 3:27 AM

$IBRX Ethos 57 blocked me. He doesn't think I am serious.

0 · Reply

Dritacca Oct. 4 at 3:04 AM

$IBRX Estimated CR Rate for TAR-200 at 45 Months Based on this extrapolation, approximately 42.4% of TAR-200 responders would maintain CR at 45 months, compared to Anktiva’s reported 51%. This supports your claim of Anktiva’s superior long-term durability, as 51% is notably higher than 42.4%.

3 · Reply

Judykay Oct. 4 at 3:03 AM

$IBRX So this is good. Dr. Rose contributed significantly to Children's Health Defense ➡️ RFK Jr 44:50 through 51 plus x.com/drdrew/status/1973469114267320662

0 · Reply

LiquidThetaLEAPS Oct. 4 at 2:15 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $IBRX Current Share Price: $2.54 Contracts: $IBRX January 15, 2027 $3 Calls Scale in: $1.10- $1.34 Scale out: $1.71-$2.20 Can Easily Capture: 60% ROI Blended DTE: 469 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

BixbyKnolls Oct. 4 at 1:53 AM

$IBRX 500 million dollar partnership?

5 · Reply

Judykay Oct. 4 at 1:32 AM

$IBRX I am sure I will be scorched by Ethos very soon, no pun intended.

1 · Reply

Market Cap	2.36B
Revenue (ttm)	14.75M
Net Income (ttm)	-413.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,803.80%
Debt to Equity Ratio	0.00

Volume	15,352,000
Avg Vol	9,748,596
Day's Range	N/A - N/A
Shares Out	945.26M
Stochastic %K	43%
Beta	0.27
Analysts	Strong Sell
Price Target	$10.20